2.18

28.24% 0.48

Traws Pharma Inc (TRAW)

Overview News Price History Discussions Forecast

Traws Pharma Inc stock is traded at $2.18, with a volume of 88.79M. It is up +28.24% in the last 24 hours and up +39.74% over the past month. Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Previous Close:

$1.70

Open:

$2.05

24h Volume:

88.79M

Relative Volume:

59.07

Market Cap:

$33.03M

Revenue:

$2.79M

Net Income/Loss:

$9.17M

P/E Ratio:

1.5924

EPS:

1.369

Net Cash Flow:

$-20.77M

1W Performance:

+46.31%

1M Performance:

+39.74%

6M Performance:

+11.79%

1Y Performance:

+55.71%

1-Day Range:

$1.79

$2.3999

1-Week Range:

$1.45

$2.3999

52-Week Range:

$0.97

$3.265

Traws Pharma Inc Stock (TRAW) Company Profile

Name

Traws Pharma Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

267-759-3680

Address

12 PENNS TRAIL, NEWTOWN

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

TRAW's Discussions on Twitter

Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAW Traws Pharma Inc	2.18	33.03M	2.79M	9.17M	-20.77M	1.369
VRTX Vertex Pharmaceuticals Inc	429.82	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	714.89	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.17	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.05	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	312.12	32.38B	5.36B	287.73M	924.18M	2.5229

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	H.C. Wainwright	Buy
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
May-18-21	Initiated	Guggenheim	Buy
Mar-01-18	Reiterated	H.C. Wainwright	Buy
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy
Apr-27-17	Initiated	Laidlaw	Buy
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy

View All

Traws Pharma Inc Stock (TRAW) Latest News

Traws Pharma Inc (TRAW)

Traws Pharma Inc Stock (TRAW) Company Profile

Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Traws Pharma Inc Stock (TRAW) Latest News

Traws Pharma Soars As Hantavirus Antiviral Plan Sparks Rally - timothysykes.com

Traws Pharma (NASDAQ: TRAW) registers 35.9M resale shares - Stock Titan

Traws Pharma to Advance Potential Hantavirus Treatment Clinical Candidates - Contract Pharma

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths - TechStock²

Traws Pops on Hantavirus Research - Baystreet.ca

Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell - Moomoo

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak - Benzinga

TRAW Stock Jumps As Traders Zero In On Momentum And Cash Runway - StocksToTrade

TRAW Stock Pops On Volatile Run As Traders Eye Breakout - timothysykes.com

Traws Pharma to Advance Clinical Candidates for Hantavirus Infections - geneonline.com

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Traws Pharma To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infections - TradingView

Traws Pharma to develop hantavirus treatment candidates By Investing.com - Investing.com Australia

Traws Pharma to develop hantavirus treatment candidates - Investing.com

Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment - Quiver Quantitative

No approved hantavirus treatment; Traws plans drug push - Stock Titan

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections - ChartMill

Number of shareholders of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView

Newtown-based Traws Pharma shares full-year results, clinical progress - MSN

OrbiMed (NASDAQ: TRAW) details 11.9% Traws Pharma stake and warrants - Stock Titan

TRAW (Traws Pharma) delivers stunning Q4 2025 EPS beat, shares rise 1.34% on upbeat investor reception.High Interest Stocks - newser.com

Traws Pharma posts 150.5% EPS surprise turning profitable vs loss estimatesElite Trading Signals - Newser

Traws Pharma, Inc. 2025 Executive Compensation, Governance, and Board of Directors Overview - Minichart

Traws Pharma (NASDAQ: TRAW) 10-K/A details board, pay and ownership - Stock Titan

Insider Stock Purchases: April 29, 2026 - Quiver Quantitative

Traws Pharma Stock (TRAW) Opinions on Insider Purchase - Quiver Quantitative

Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com South Africa

Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com UK

TRAW Traws Pharma delivers massive Q4 2025 earnings beat, shares gain 7.44 percent on positive investor sentiment.Management Guidance - Newser

TRAW | Traws Pharma, Inc. Common Insider Trading - Quiver Quantitative

OrbiMed acquires $998,207 in Traws Pharma common stock By Investing.com - Investing.com Australia

OrbiMed acquires $998,207 in Traws Pharma common stock - Investing.com

OrbiMed (NASDAQ: TRAW) adds Traw Pharma stock and warrant stake - Stock Titan

TRAW - Finviz

Traws Pharma (TRAW) price target decreased by 24.14% to 5.61 - MSN

Traws Pharma, Inc. (TRAW) forms 'hammer chart pattern': Time for bottom fishing? - MSN

Newtown-Based Traws Pharma Shares Full-Year Results, Clinical Progress - BUCKSCO.Today

Traws Pharma Inc. notches 43.1% EPS beat on narrower lossCommunity Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai

Traws Pharma Q4 2025 Earnings Call Transcript - MarketBeat

Traws Pharma (TRAW) Sector Trends | Traws Pharma Inc. notches 43.1% EPS beat on narrower lossOptions Activity - Cổng thông tin điện tử Tỉnh Sơn La

Traws Pharma Reports 2025 Results, Secures Up to $60M Financing - MyChesCo

Traws Pharma (TRAW) Stock Breakdown Level (Smart Money Flows) 2026-04-20Viral Momentum Stocks - UBND thành phố Hải Phòng

Traws Pharma Secures Up to $60 Million in Private Placement Financing - Global Legal Chronicle

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Cash per share of Traws Pharma, Inc. – MUN:0T20 - TradingView

Is Traws Pharma (TRAW) a Possible Value Trap After FY2025 Result - GuruFocus

TRAW Stock Chart | TRAWS PHARMA INC (NASDAQ:TRAW) - ChartMill

Traws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027 - MSN

Earnings call transcript: Traws Pharma Q4 2025 shows strategic shift boosts revenue By Investing.com - Investing.com South Africa

Earnings call transcript: Traws Pharma Q4 2025 shows strategic shift boosts revenue - Investing.com

Traws Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Traws Pharma Inc Stock (TRAW) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to TRAW